Compare FIEE & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FIEE | AYTU |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | 43 | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.0M | 23.4M |
| IPO Year | N/A | N/A |
| Metric | FIEE | AYTU |
|---|---|---|
| Price | $4.56 | $2.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $9.33 |
| AVG Volume (30 Days) | N/A | ★ 130.1K |
| Earning Date | N/A | 02-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $63,696,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $47.32 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | N/A | $0.95 |
| 52 Week High | N/A | $3.07 |
| Indicator | FIEE | AYTU |
|---|---|---|
| Relative Strength Index (RSI) | 74.42 | 53.41 |
| Support Level | $3.39 | $2.60 |
| Resistance Level | $3.70 | $2.85 |
| Average True Range (ATR) | 0.28 | 0.18 |
| MACD | 0.08 | -0.02 |
| Stochastic Oscillator | 81.53 | 13.83 |
FiEE Inc, formerly Minim Inc is a digital service provider focused on integrating artificial intelligence and data analytics into content creation and brand management. The company offers a range of services designed to support creators, artists, and businesses in developing, managing, and optimizing their digital presence across various platforms, including customized graphic and posts, short videos, and editorial calendars aligned with brand goals.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.